Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference

SANTA MONICA, Calif., March 19, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, being held March 20-21 at the Westin Grand Central Hotel in New York City.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit: www.opiant.com.

CONTACTS:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746